[go: up one dir, main page]

SG11202113075WA - Methods for determining the likelihood of lung cancer - Google Patents

Methods for determining the likelihood of lung cancer

Info

Publication number
SG11202113075WA
SG11202113075WA SG11202113075WA SG11202113075WA SG11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA
Authority
SG
Singapore
Prior art keywords
likelihood
determining
methods
lung cancer
lung
Prior art date
Application number
SG11202113075WA
Inventor
Boon Cher Goh
Lingzhi Wang
Sok Hwee Cheow
Henry Yang
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG11202113075WA publication Critical patent/SG11202113075WA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202113075WA 2019-06-21 2020-06-19 Methods for determining the likelihood of lung cancer SG11202113075WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201905757Q 2019-06-21
PCT/SG2020/050343 WO2020256640A1 (en) 2019-06-21 2020-06-19 Methods for determining the likelihood of lung cancer

Publications (1)

Publication Number Publication Date
SG11202113075WA true SG11202113075WA (en) 2021-12-30

Family

ID=74040939

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113075WA SG11202113075WA (en) 2019-06-21 2020-06-19 Methods for determining the likelihood of lung cancer

Country Status (6)

Country Link
US (1) US20220397575A1 (en)
EP (1) EP3987292A4 (en)
JP (2) JP7691373B2 (en)
CN (1) CN114026424A (en)
SG (1) SG11202113075WA (en)
WO (1) WO2020256640A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116338191A (en) * 2023-03-13 2023-06-27 杭州华然腾创生物科技有限公司 Lung cancer exosome protein marker based on flow technology and application thereof in aspect of lung cancer screening
WO2025028453A1 (en) * 2023-07-31 2025-02-06 国立大学法人大阪大学 Lung cancer biomarker
CN120559238A (en) * 2025-05-27 2025-08-29 中国人民解放军总医院第一医学中心 Application of protein markers in the preparation of products for distinguishing benign and malignant ground-glass nodules in the lungs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040227L (en) * 2004-02-13 2005-08-14 Jurilab Ltd Oy A method for detecting the risk of cancer, coronary heart disease and stroke
EP2340506B1 (en) * 2008-09-09 2015-11-11 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2012048372A1 (en) * 2010-10-11 2012-04-19 Medsaic Pty Ltd Assay for disease detection
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L Circulating biomarkers
US20150152474A1 (en) * 2012-03-09 2015-06-04 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
CA3008272A1 (en) * 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018191560A1 (en) * 2017-04-12 2018-10-18 Proterixbio, Inc. Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms
WO2018216009A1 (en) * 2017-05-22 2018-11-29 The National Institute For Biotechnology In The Negev Ltd. Ben-Gurion University Of The Negev Biomarkers for diagnosis of lung cancer
CN111971560B (en) * 2017-12-01 2024-06-11 康奈尔大学 Nanoparticles and different exosome subsets for cancer detection and treatment
CN110527726A (en) * 2018-05-25 2019-12-03 国家纳米科学中心 The excretion body detection device and application for detecting for non-small cell lung cancer and judging by stages

Also Published As

Publication number Publication date
JP7691373B2 (en) 2025-06-11
WO2020256640A1 (en) 2020-12-24
JP2025061032A (en) 2025-04-10
EP3987292A4 (en) 2023-10-11
JP2022537820A (en) 2022-08-30
CN114026424A (en) 2022-02-08
EP3987292A1 (en) 2022-04-27
US20220397575A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
EP3443119B8 (en) Methods for lung cancer detection
IL270717A (en) Biomarkers for diagnosis of lung cancer
EP3607089A4 (en) Plasma based protein profiling for early stage lung cancer prognosis
IL292727A (en) Multispecific antibody
NO20220017A1 (en) Determining the volume of cuttings
SG11202101397TA (en) Biomarkers for cancer therapy
GB201919219D0 (en) Cancer biomarkers
IL276009A (en) Kits and methods for diagnosing lung cancer
EP4022094A4 (en) Biomarkers for the diagnosis of lung cancers
HUE054864T2 (en) In vitro method for the diagnosis of lung cancer
SG11202113075WA (en) Methods for determining the likelihood of lung cancer
GB201915469D0 (en) Cancer detection methods
GB201906201D0 (en) Method for the detection of protate cancer
GB201908591D0 (en) Methods for cancer diagnosis
GB2580963C (en) Cancer therapies
SG11202006997SA (en) A method of determining a risk of cancer
ZA202107946B (en) Methods for the diagnosis of lung cancer
SI3794148T1 (en) Methods for the diagnosis of aneurysm or cancer
GB201905861D0 (en) Methods of detecting cancer
GB201906199D0 (en) Method for the detection of cancer
GB201911216D0 (en) Methods of determining the margin of a tumour
GB201910444D0 (en) Methods of diagnosing cancer
GB201914096D0 (en) Cancer Biomarker
EP3847282A4 (en) Biomarkers for cancer therapy
GB201908085D0 (en) Methods of determining cancer